Suscribirse

Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4+Foxp3+ regulatory T cells - 03/06/22

Doi : 10.1016/j.biopha.2022.113187 
Shaokui Chen a, 1, Ruixin Li a, 1, Yibo Chen a, Chon-Kit Chou a, Zhexuan Zhang b, Yang Yang a, Ping Liao a, Qingqing Wang c, Xin Chen a, d, e, f,
a Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, 999078, Macao Special Administrative Region of China, China 
b College of Science, Hunan University of Technology and Business, Changsha 410205, China 
c Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China 
d Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, 999078, Macao Special Administrative Region of China, China 
e MoE Frontiers Science Center for Precision Oncology, University of Macau, 999078, Macao Special Administrative Region of China, China 
f Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, University of Macau, 999078, Macao Special Administrative Region of China, China 

Correspondence to: Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa 999078, Macao Special Administrative Region of China.Institute of Chinese Medical Sciences, University of MacauAvenida da UniversidadeTaipa999078Macao Special Administrative Region of China

Abstract

One characteristic of tumor-associated CD4+Foxp3+ regulatory T cells (Tregs) is the high expression of tumor necrosis factor receptor type II (TNFR2), a receptor that mediates the decisive effect of tumor necrosis factor (TNF) in the activation and expansion of Tregs. There is increasing evidence that inhibition of TNFR2 can enhance anti-tumor immune responses. Therefore, we screened Chinese herbal extracts for their capacity to block TNF-TNFR2 interaction. The results showed that the treatment with a Chinese herb extract could inhibit TNFR2-induced biological responses in vitro, including the proliferation of TNFR2+ Tregs. Our subsequent study led to the identification of flavonoid compound scutellarin was responsible for the activity. Our results showed that scutellarin is able to disrupt the interaction of TNF-TNFR2 and inhibited the phosphorylation of p38 MAPK, a down-stream signaling component of TNFR2. Importantly, in vivo scutellarin treatment markedly enhanced the efficacy of tumor immunotherapy with CpG oligodeoxynucleotide in mouse CT26 colon cancer model. This effect of scutellarin was associated with the reduction of the number of tumor-infiltrating TNFR2-expressing Tregs and increased tumor infiltration of interferon-γ–producing CD8+ T cells. Our result also suggests that scutellarin or its analogs may be used as an adjuvant to enhance the anti-tumor effect of immunotherapeutic agent by eliminating TNFR2+ Treg activity.

El texto completo de este artículo está disponible en PDF.

Keywords : CD4+Foxp3+ regulatory T cells, Tumor necrosis factor, Tumor necrosis factor receptor II, Scutellarin, CpG oligodeoxynucleotide, Cancer immunotherapy


Esquema


© 2022  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 151

Artículo 113187- juillet 2022 Regresar al número
Artículo precedente Artículo precedente
  • The whole transcriptome analysis and the circRNA-lncRNA network construction in arsenic trioxide-treated mice myocardium
  • Yanan Jiang, Xiuyun Shen, Chaorun Dong, Fengnan Zhi, Yang Gao, Chunpeng Shi, Yuqiu Chao, Jincheng Xu, Desi Shang, Juan Xu, Baofeng Yang, Xia Li, Yunlong Bai
| Artículo siguiente Artículo siguiente
  • Phytochemicals as new therapeutic candidates simultaneously stimulate proliferation and counteract senescence of stem cells
  • Tie-Jun Yuan, Xue-Han Xu, Nan Zhou, Ge Yan, Ting-Wei Gu, Li-Hua Peng

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.